Biomarker ID | 820 |
PMID | 22126577 |
Year | 2011 |
Biomarker | Interleukin-10 (IL-10) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Increased expression in patients with poor survival |
Odds Ratio/Hazard Ratio/Relative Risk | HR = 0.37 (95% CI: 0.18-0.69) |
Effect on Pathways | Pathways Include:-Autoimmune thyroid disease,Leishmaniasis,Allograft rejection,Amoebiasis,SMAD2/3 nuclear pathway |
Experiment | Survival Vs No Survival |
Type of Biomarker | Prognostic |
Cohort | Of a total of 149 patients, 71 had biopsy proven prostate cancers (TNM stage: T2=17, T3=26 and T4=28) and 78 clinical benign prostate hyperplasia (BPH).71 age matched controls were also selected |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | ELISA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | IL10 |